Welcome to Multibagg AI
Log in to access personalized features
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q2 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q1 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q4 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Investor Presentation
Q3 FY24
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Dashboard
Portfolio
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Emami Ltd (EMAMILTD) is currently trading at 407.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Emami Limited is a leading FMCG company in India, specializing in personal care and healthcare products, with prominent brands like Navratna, BoroPlus, and Zandu in its portfolio. In Q3FY26, Emami achieved strong performance with consolidated net sales of ₹1,147 crore, growing by 11%, driven by a robust 9% volume growth in its domestic market and 9% growth in international business. The company showcased successful innovation and portfolio expansion, launching products such as Kesh King Gold and BoroPlus variants. This strategy aligned with their focus on premiumization and capturing evolving consumer needs. Emami's omnichannel approach has been effective, with organized channels contributing 32% of revenues. The company's digital strategy is advancing, with digital spending accounting for 50% of media expenses, enabling targeted consumer engagement. The company declared a dividend of ₹6 per share as the second interim dividend for FY26, illustrating Emami's confidence in its financial performance and commitment to rewarding shareholders.
Over the past 52 weeks, Emami Ltd has traded between a low of ₹385.35 and a high of ₹655.40. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Emami Ltd has a market capitalization of approximately 17,477.46. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Emami Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 21.85 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 17,477.46 Cr, Emami Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Emami Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Emami Ltd is 21.85. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Emami is paying up to ₹200 crore in cash to acquire the remaining stake and gain full 100% ownership of Axiom Ayurveda.
The rules are being implemented in a phased manner, with major changes like the increase in contract size and reduction in weekly expiries starting from November 20, 2024.
The most significant positive is the government's major push for the Ayurveda sector, including setting up new institutes and upgrading labs. This directly benefits Emami's strong Ayurvedic portfolio, led by the Zandu brand, by enhancing credibility and market demand.
Bearish
4
Neutral
7
Bullish
3
Bearish
25
Neutral
7
Bullish
14
Bearish
21
Neutral
0
Bullish
11
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
9712.95 | 31,497 Cr | 36.68 | 33.82 | 1.80 | 88.76 | 122.07 | 40.29 | ||
7498.20 | 24,437 Cr | 39.38 | 21.02 | 1.49 | 49.37 | 66.89 | 28.87 | ||
397.65 | 17,477 Cr | 21.85 | 5.96 | 2.50 | 25.72 | 27.90 | 21.64 | ||
87.59 | 11,907 Cr | 142.00 | 31.23 | 0.00 | 16.19 | 20.67 | 18.88 | ||
304.30 | 9,909 Cr | 63.81 | 7.80 | 0.00 | 10.35 | 12.95 | 8.22 | ||
383.30 | 5,007 Cr | 32.13 | 7.76 | 0.00 | 21.16 | 25.19 | 18.65 | ||
785.00 | 1,422 Cr | 55.91 | 13.25 | 0.00 | 21.21 | 22.40 | 13.32 | ||
| Median: 7 Co. | — | 397.65 | 11,907 Cr | 39.38 | 13.25 | 0.00 | 21.21 | 25.19 | 18.88 |
Acquisition / M&A
Emami executed a definitive agreement (1 Apr 2026) to acquire the remaining ~73.5% in Axiom Ayurveda (AloFrut), having taken an additional ~36.7% (existing ~26.5%); transaction to close within ~3 months for up to Rs.200 crore; Axiom FY26 topline ~Rs.180cr; new CEO appointed.
Merger/Acquisition
Emami executed a definitive agreement to acquire the remaining ~73.5% stake in Axiom Ayurveda (AloFrut) for up to Rs.200 crore; the phased transaction (first tranche added ~36.7%) is expected to close within ~3 months, marking Emami's entry into the beverage sector.
Merger/Acquisition
Emami Ltd. acquired 8,430,909 equity shares (~36.7%) of Axiom Ayurveda Pvt. Ltd. on 1 Apr 2026 under a Share Purchase Agreement, making AAPL its subsidiary; remaining ~36.7% (8,430,909 shares) to be acquired by June 2026.
Acquisition Update
Emami entered into a SPA to buy ~73.5% of Axiom Ayurveda (existing stake ~26.5%); it acquired 84,30,909 shares (~36.7%) on 1 Apr 2026 making AAPL a subsidiary, with remaining shares to be acquired by Jun 2026.
Merger/Acquisition
On 31 Mar 2026 Emami's board approved purchase of ~73.5% of Axiom Ayurveda for cash consideration up to Rs.200 crore, raising its stake to 100% and making AAPL a wholly‑owned subsidiary; expected by 30 Jun 2026.
Merger/Acquisition
Emami Board approved purchase of ~73.5% of Axiom Ayurveda for up to Rs.200 crore in cash, raising its stake to 100% and making Axiom a wholly‑owned subsidiary; deal expected by 30 June 2026.
Emami Limited is a leading FMCG company in India, specializing in personal care and healthcare products, with prominent brands like Navratna, BoroPlus, and Zandu in its portfolio.
In Q3FY26, Emami achieved strong performance with consolidated net sales of ₹1,147 crore, growing by 11%, driven by a robust 9% volume growth in its domestic market and 9% growth in international business.
The company showcased successful innovation and portfolio expansion, launching products such as Kesh King Gold and BoroPlus variants. This strategy aligned with their focus on premiumization and capturing evolving consumer needs.
Emami's omnichannel approach has been effective, with organized channels contributing 32% of revenues. The company's digital strategy is advancing, with digital spending accounting for 50% of media expenses, enabling targeted consumer engagement.
The company declared a dividend of ₹6 per share as the second interim dividend for FY26, illustrating Emami's confidence in its financial performance and commitment to rewarding shareholders.
Personal Products
Personal Care
17,477 Cr
Low Risk
21.8
41.7
1.5
6.0
655.40
385.35
Sales CAGR
Profit CAGR
ROE
ROCE
